CRF Health, the developer of the TrialMax Suite of electronic Clinical Outcome Assessment Solutions (eCOA) for the life sciences industry, became the first eCOA company to complete a full validation study for professor Elizabeth F. Juniper’s ACQ and AQLQ questionnaires to the “Gold Standard” based on her recently released “Levels of Acceptability of Electronic Versions” rating system.
CRF Health continually collaborates with instrument authors to achieve the highest level of compliance with their instruments to assure data integrity.
CRF Health has now deployed spirometer integration together with the ACQ and AQLQ in several global studies on TrialMax Touch and TrialMax Slate with four major pharmaceutical companies. Including these programs, CRF Health’s clinical reach and breadth using Juniper’s instruments spans nearly 40 countries, 3,000 patients and more than 40 languages. In addition to these, CRF Health has deployed a further 15 studies using Juniper’s ACQ and AQLQ instruments (but without spirometer integration).
TrialMax solutions are available for five platforms including Windows, Windows Mobile, Android, Palm OS and Web, thus allowing clients to select the right platform, technology and hardware to support their clinical trials. The combination of CRF Health’s clinical expertise and innovation of ePRO collection methods, combined with patient engagement and retention tools, offer new ways to improve study execution and subject compliance.
“I feel it is important, when evaluating a new technology device to determine whether it will give valid data, to keep in mind that validity is more likely to be achieved if the screen shots are similar to the original format especially when translating languages with longer text,” said Juniper in a recent study discussion.
As the most flexible eCOA solution in the industry, TrialMax offers superior usability to patients, sites and sponsors. CRF Health’s flexible, collaborative design tool, TrialStudio, facilitates the rapid implementation of electronic Patient Reported Outcome instruments. By leveraging the TrialMax Suite, CRF Health is clearly the leader in maintaining the integrity of instrument authors’ research and designs. In addition, the provision of world class support to patients, clinicians, sites and sponsors ensures high levels of usability and compliance.
“Professor Elizabeth Juniper’s diligence and research integrity is a model for the industry. We are excited to have had the opportunity to collaborate and to jointly achieve this industry milestone,” said Rachael Wyllie, CEO of CRF Health. “It is through our engagement with researchers and instrument authors such as professor Elizabeth Juniper that we continually enhance our regulatory rigor, technology competence and patient research integrity through clinical expertise and innovation.”
